Evidence map›Paper›PMID 39540705›Full record

ArticleJournal of diabetes investigation2025

Which is the real nature of glucose-dependent insulinotropic peptide?: Endogenous vs pharmacological.

Yuji Yamazaki, Yutaka Seino

Abstract readEditorial
In one paragraph

Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Fat Quality, Not Just Quantity: Incretin-Based Therapy and Fat Composition in Type 2 Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yuji YamazakiCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.ORCID https://orcid.org/0009-0007-5876-8695
Yutaka SeinoCenter for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0002-1099-7989

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GIP is a multifaceted hormone whose role in metabolism is highly context-dependent. Pharmacological GIP receptor activation promotes weight loss and improves insulin sensitivity, contrasting sharply with the lipogenic and insulin-resistant effects of endogenous GIP. However, it remains unclear whether these effects simply amplify endogenous GIP's actions or represent distinct mechanisms.

Indexed as

Gastric Inhibitory PolypeptideAnimalsHumansInsulin ResistanceReceptors, Gastrointestinal HormoneGastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorReceptors, Gastrointestinal Hormone

Identifiers

PMID39540705
PMCPMC11786169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.